Member Info for NFTs

Once Lanstead have finished clearing to pay NFX by selling the SP will crash further as it’s been purposely held up to offload their A trades at near to the buy price. Been so manipulated to hold this up.

When that support goes as the MM’s we’re making cash out the set trades it will be turned off and the SP will then be manipulated further down as no support.

As I say.

Money tap is now turning off as Lanstead leave the building.

Where does the income come from the virtual business to keep their virtual salaries paid? Accounts, broker, legal team plus business trips to try get a business.

It’s not a good place to be in this climate as pharmaceuticals are actually holding back. Maybe next year but in the meantime you, me and I have to take another dilution hit which as mentioned should been done last year to keep this going till end next year.

Now 500,000 cash raised here is going to hurt. 40% dilution incoming but of course if and when they find a partner they will pay a few mil but nothing mega that is for sure.

Issued no price is all you needed to know. Down down!! People left holding the baby as the insiders all walked it up took your cash and did a dash

As I said nothing this year or more importantly before reserves need boosting.

I’d say AGM fresh round September. No deal coming anytime soon if significance and the cash cow ends next month. So Lanstead run out but then we don’t really know who sold and selling from last round. Guess they will be taking up more again.

No

That’s before it failed on rats as a stand-alone treatment for IPF. Durability after heavy dosing failed

It got pulled they then changed tact to a SOC lesser treatment with some very basic sliver of lung tissue in a petri dish like they did in 2019 data. It’s moved backwards and the coffers are empty NXP001 locked permanently away for £50,000 k and NXP004 May reduce quantity of white powder usage and no money to move it, nobody interested and money nearly out.

Tick rock muggins o’clock

All sucked into Lala land.

It’s only part finished pre clinical not phase 1 ready and only for SOC not standalone. No chance, I repeat no chance this year and they need cash!!!! So hold and dilute ready for a potential sale but be sometime yet and the cash cow Lanstead empties soon ding a ling

Jimbo say Tim the salesman playing the thing dingaling as they suck it in on all of a sudden great info planted thing lol suck it up ting a ling, till they go ding dong ooops

What’s to hide? Don’t they trust them?

Have they doubts about anything coming from this? Quick in and out with potential freebie’s if by chance they can secure some early interest at this early stage of preclinical?

People trotting about as if this is now a given. It’s miles away from being proven and as mentioned before they have a problem after the rat data. That showed issues with durability in a living organism and that’s an issue. Drops onto a slice of lung tissue in a Petri dish is all well and good but this clashes with rats breathing in this exact powdered cocrystal formula at very low levels then at very high levels and then it was pulled!!! Why did they stop the tests before announcing the data when they had another go when it was already well underway?

They spent in excess of a million doing that rat data.

To then stop after previous fails and rebrand it as new SOC treatment which we already understood from the data Chris Blackwell announced end 2020!

It’s got something lurking in the background hence why the placing holder is hiding to avoid mud on their face if it fails.

George, asking why the directors want to hide the placing holder who they negotiated with is not a wild bipolar question lol

Strange nobody asks the BOD as you have a nice boiler room with Tim and Co sales reps flogging the loaded questions to push agenda! Group think and herds mentality etc

This is the placing holder George lol

This is the placing holder who NFX BOD negotiated with and know who they are. Therefore the BOD have a duty also to provide the market accordingly as they know the placing holder. It’s different when it’s a pi who is more difficult to find on the share register!

Why are Nuformix hiding the placing holding institution who bought 4/5% of the holding at 0.2p yet don’t announce their position as per requirement? Guess they just flogging in the background as Lanstead etc use their MM control to manipulate the tiny SP to drip feed to those gullible enough to throw cash in the hole!

There is a lot of nervous holders here trying very hard to drown out real issues and questions here.

Most of these are people who jumped in thinking this would be the easiest 10 bagger out there without reading the very very long history of trying to achieve anything here..

Company is very much on its last hurrah in getting a chance to do anything significant with what little they generated.

As you keep being told to look out there at other data produced by other companies in China etc regarding Tranilast that Nuformix want to try latch onto as their very limited trial data is that!! Limited so to negotiate they need to talk about other peoples data which they won’t have proper access to without paying cash!

Cash cash cash where is the cash etc… tick tick tick as the money drains out of the pot.

Lol, it’s been available for 3 years and the data is not unequivocally good!!!

The rat data is more detailed that’s why it cost a million etc and it’s got a massive X marking bad durability of action.

That is a fact!! It’s a problematic issue!

Looking ahead you will have plenty of opportunities to buy if you love this company over the coming months. Why rush like all the others it will need to gain funds prior to any deals as the purse is empty. March23 results are behind payments which they need to make for the latest tests. They start at around £250,000 plus. Do the maths. Then add running costs and paying accountants and the virtual BOD who are here to take their wages.

Q&A is a desperation to try maintain some kind of noise and interest here whilst Lanstead continue their monthly selling till Aug/Sep when the final payments of the 20 months which started Dec 21!

After that the company has ZERO income and will rapidly fall into cessation unless funding is done, hence Sept AGM.

That’s a long time to try keep holders holding and hence an importance to try maintain current SP before it becomes completely worthless.

Absolutely no need to be buying here until funding is done.

Need to get things in order before AGM

Https://find-and-update.company-information.service.gov.uk/company/12970979/officers

It’s done in a way that deflected attention and paints a picture that Chris/Anne/Alistair/Kirk etc look to be the issue but when you look at the dates and then look at who dissolved it and who they are and what they operate you can see that is not the picture.

“Oxilio Acquisition of LSHS Consulting

Oxford, 30th March 2022 – Oxilio, the pioneering oncology company, repurposing existing drugs to address unmet needs in cancer therapy, today announces that it has acquired LSHS Consulting Limited in a share transaction.

LSHS is a specialist life science consultancy firm established by Dr Dan Gooding, comprising intellectual property assets relevant to Oxilio’s OXL001 programme.

Dr Gooding was CEO of Nuformix plc until June 2020 and has significant experience in the pre-clinical and clinical development of formulations relevant to OXL001. Through him, Oxilio commenced discussions for the licensing of Nuformix’s NXP-001 cocrystal aprepitant formulation for the treatment of cancer.

Dr Gooding has been instrumental in helping Oxilio make rapid scientific and commercial progress with both our co-crystal and lipid-based formulation routes, in addition to the exploration of further formulation technologies which remain under evaluation.

Dr Gooding also introduced Oxilio to TRx Biosciences and facilitated the negotiation of our exclusive licence to use TRX’s lipid platform technology with our aprepitant formulation, again for the treatment of cancer. Since that time, Dr Gooding has become a Director of TRx Biosciences.

As a result of the transaction, Oxilio secures continuing access to Dr Gooding’s expertise and know-how in both our lipid and co-crystal product development routes.

Dr Gooding has undertaken much of our formulation development work with the TRx scientists and provided the additional capability and expertise Oxilio requires to transfer this technology to Quotient Sciences for clinical trials.

We are looking forward to continuing close co-operation with Dr Gooding across a range of scientific developments at Oxilio.”